Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
Binqing Q. Wei, Kirk D. Robarge, Sharada S. Labadie et al. · Bioorganic & Medicinal Chemistry Letters · 2022
Cited by 0 works. doi:10.1016/j.bmcl.2022.128576
Authors
- Binqing Q. Wei
- Kirk D. Robarge
- Sharada S. Labadie
- Jinhua Chen
- Laura Corson
- Antonio G. DiPasquale
- Peter S. Dragovich
- Charles W. Eigenbrot
- Marie Evangelista
- Benjamin P. Fauber
- Rebecca Hong
- Kwong Wah Lai
- Wenfeng Liu
- Shuguang Ma
- Shiva Malek
- Thomas O’Brien
- Jodie Pang
- Laurent Salphati
References
- Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance
- MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening
- Targeting lactate metabolism for cancer therapeutics
- Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer
- Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer
- Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)
- Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase
- Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice